PMID- 32996666 OWN - NLM STAT- MEDLINE DCOM- 20210713 LR - 20210713 IS - 1365-2869 (Electronic) IS - 0962-1105 (Linking) VI - 30 IP - 3 DP - 2021 Jun TI - Mechanisms of intermittent hypoxia-mediated macrophage activation - potential therapeutic targets for obstructive sleep apnoea. PG - e13202 LID - 10.1111/jsr.13202 [doi] AB - Intermittent hypoxia (IH) plays a key role in the pathogenesis of insulin resistance (IR) in obstructive sleep apnoea (OSA). IH induces a pro-inflammatory phenotype of the adipose tissue with M1 macrophage polarisation, subsequently impeding adipocyte insulin signalling, and these changes are in striking similarity to those seen in obesity. However, the detailed molecular mechanisms of IH-induced macrophage polarisation are unknown and identification of same should lead to the identification of novel therapeutic targets. In the present study, we tested the hypothesis that IH acts through similar mechanisms as obesity, activating Toll-like-receptor (TLR)4/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) and nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) signalling pathways leading to the upregulation and secretion of the key cytokines interleukin (IL)-1beta and IL-6. Bone-marrow derived macrophages (BMDMs) from lean and obese C57BL/6 male mice were exposed to a state-of-the-art in vitro model of IH. Independent of obesity, IH led to a pro-inflammatory M1 phenotype characterised by increased inducible nitric oxide synthase and IL-6 mRNA expression, robust increase in NF-kappaB DNA-binding activity and IL-6 secretion. Furthermore, IH significantly increased pro-IL-1beta mRNA and protein expression and mature IL-1beta secretion compared to control treatment. Providing mechanistic insight, pre-treatment with the TLR4 specific inhibitor, TAK-242, prevented IH-induced M1 polarisation and upregulation of IL-1beta mRNA and pro-IL-1beta protein expression. Moreover, IH-induced increase in IL-1beta secretion was prevented in BMDMs isolated from NLRP3 knockout mice. Thus, targeting TLR4/NF-kappaB and NLRP3 signalling pathways may provide novel therapeutic options for metabolic complications in OSA. CI - (c) 2020 European Sleep Research Society. FAU - Fitzpatrick, Susan F AU - Fitzpatrick SF AD - School of Medicine, Conway Institute, University College Dublin, Dublin, Ireland. FAU - King, Ailbhe D AU - King AD AD - School of Medicine, Conway Institute, University College Dublin, Dublin, Ireland. FAU - O'Donnell, Cliona AU - O'Donnell C AD - Pulmonary and Sleep Disorders Unit, St Vincent's University Hospital, Dublin, Ireland. FAU - Roche, Helen M AU - Roche HM AD - Nutrigenomics Research Group, School of Public Health, Physiotherapy and Sports Science, UCD Institute of Food and Health, Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland. AD - Institute for Global Food Security, Queen's University Belfast, Belfast, UK. FAU - Ryan, Silke AU - Ryan S AUID- ORCID: 0000-0003-0963-255X AD - School of Medicine, Conway Institute, University College Dublin, Dublin, Ireland. AD - Pulmonary and Sleep Disorders Unit, St Vincent's University Hospital, Dublin, Ireland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200930 PL - England TA - J Sleep Res JT - Journal of sleep research JID - 9214441 SB - IM MH - Animals MH - Macrophage Activation/*physiology MH - Male MH - Mice MH - Sleep Apnea, Obstructive/*therapy OTO - NOTNLM OT - IL-1beta OT - NLRP3 inflammasome OT - Toll-like-receptor 4 OT - intermittent hypoxia OT - macrophages OT - obstructive sleep apnoea EDAT- 2020/10/01 06:00 MHDA- 2021/07/14 06:00 CRDT- 2020/09/30 08:45 PHST- 2020/08/31 00:00 [revised] PHST- 2020/07/17 00:00 [received] PHST- 2020/09/06 00:00 [accepted] PHST- 2020/10/01 06:00 [pubmed] PHST- 2021/07/14 06:00 [medline] PHST- 2020/09/30 08:45 [entrez] AID - 10.1111/jsr.13202 [doi] PST - ppublish SO - J Sleep Res. 2021 Jun;30(3):e13202. doi: 10.1111/jsr.13202. Epub 2020 Sep 30.